
Enlicitide in Primary Prevention: What PREVENT Data Show
Ann Marie Navar, MD, PhD, explains how PREVENT improves on the pooled cohort equations by starting at age 30 and adding 30-year risk estimates.
In an interview with Pharmacy Times, Ann Marie Navar, MD, PhD, professor of medicine at UT Southwestern Medical Center, discussed how the American Heart Association’s (AHA) Predicting Risk of cardiovascular disease EVENTs (PREVENT) calculator can guide
Navar explained that cholesterol guidelines from the AHA and the American College of Cardiology have long relied on risk assessment tools to identify people in primary prevention who are at highest risk of heart disease and may have the most to gain from lipid lowering. According to Navar, PREVENT substantially improves on the pooled cohort equations at identifying who is at highest risk and at quantifying that risk. She highlighted 2 features that were especially important for the guidelines: PREVENT starts at age 30 rather than age 40, and it provides 30-year risk estimates, so clinicians can identify people at high long-term risk for lipid-lowering therapy earlier in life.
Turning to enlicitide, Navar said she was not surprised that LDL-C lowering was consistent across PREVENT risk categories, noting that other CORALreef analyses have shown consistent LDL lowering with the drug. The purpose of the analysis, she said, was to provide more detailed data for individuals considering enlicitide for primary prevention. She added that the trial did not show lower-risk participants becoming less adherent or more likely to change background therapy, which she called reassuring for extending the results to general practice.
Related to this article








